Sanofi SA (SNY) on Tuesday said that the European Commission has given the green light to Wayrilz or rilzabrutinib for treating immune thrombocytopenia in adults who haven't had success with other treatments.
This follows a positive recommendation from the European Medicines Agency's CHMP. Wayrilz is a new oral, reversible BTK inhibitor that aims to tackle the immune system issues causing ITP through a multi-immune modulation approach.
The decision is backed by findings from the phase 3 LUNA 3 study, which revealed notable improvements in durable platelet response, quicker response times, and enhanced quality of life compared to a placebo. Wayrilz is already approved in both the United States and the UAE.
SNY is currently trading at $48.49, up $0.46 or 0.95 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.